Table 2. Comparison of clinical parameters between positive expression and negative expression of lymphocytes and AR antibodies.
| Immune inflammationa | AR | |||
|---|---|---|---|---|
| + | – | + | – | |
Age,  ±s.d. (years) |
75.1±6.7 (n=66) | 73.1±6.9 (n=39) | 75.3±7.0 (n=48) | 74.0±6.4 (n=57) |
Duration of disease,  ±s.d. (years) |
4.3±3.2 (n=66) | 3.6±2.5 (n=39) | 4.8±4.0 (n=48) | 5.2±5.8 (n=57) |
PSA,  ±s.d. (ng ml−1) |
7.5±3.8 (n=60)* | 5.4±3.5 (n=39) | 7.1±4.3 (n=46) | 6.3±3.9 (n=53) |
TPV,  ±s.d. (ml) |
62.7±26.6 (n=60)* | 49.2±22.9 (n=34) | 51.6±27.2 (n=41)# | 62.6±25.4 (n=53) |
| TURP (%) | 62.3% (n=48) | 37.7% (n=29) | 50.6% (n=39) | 49.4% (n=38) |
| Open prostatectomy (%) | 64.3% (n=18) | 35.7% (n=10) | 32.1% (n=9) | 67.9% (n=19) |
| History of AUR (%) | 64.7% (n=22) | 35.3% (n=12) | 47.1% (n=16) | 52.9% (n=18) |
Abbreviations: AR, androgen receptor; AUR, acute urinary retention; n, valid data patient; PSA, prostate-specific antigen; TPV, total prostate volume; TURP, transurethral resection of prostate; (–), absence of expression; (+), presence of expression.
a
Immune inflammation, if immune inflammation score was more than two.
*P<0.05, compared with non-immune inflammation group.
#
P<0.05, compared with AR expression negative group.